Physician profile
Welton C Washington
NPI 1841201290
$1,441,454.31
in general payments reported to CMS, 2019-2025
19 companies · $489K in 2025
The $489K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112K · 2020: $34K · 2021: $80K · 2022: $162K · 2023: $272K · 2024: $291K · 2025: $489K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $931K · Travel and Lodging: $51K · Consulting Fee: $41K · Food and Beverage: $30K · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $930,630.25 |
| Travel and Lodging | $51,382.65 |
| Consulting Fee | $40,893.00 |
| Food and Beverage | $29,806.59 |
| Education | $167.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $377,098.31 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $236,000.07 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $177,653.04 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $176,702.18 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Abbvie INC. | $156,121.86 | 2021-2025 | Vraylar |
| Vanda Pharmaceuticals INC. | $140,983.91 | 2019-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $138,787.73 | 2024-2025 | Cobenfy |
| Allergan, INC. | $17,296.43 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $9,955.09 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $9,794.71 | 2019 | |
| Janssen Pharmaceuticals, INC | $314.08 | 2019-2025 | Invega Sustenna |
| Indivior INC. | $280.82 | 2022-2024 | Perseris, Sublocade |
| Neurocrine Biosciences, INC. | $144.99 | 2020-2025 | Ingrezza |
| Corium, LLC | $130.89 | 2023 | Adlarity |
| Lundbeck LLC | $59.52 | 2020-2025 | Rexulti |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $53.25 | 2022 | |
| Axsome Therapeutics, INC. | $32.51 | 2023 | Auvelity |
| Idorsia Pharmaceuticals US INC | $32.43 | 2023 | Quviviq |
| Supernus Pharmaceuticals, INC. | $12.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Welton Washington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.